Research programme: anti-factor XI monoclonal antibodies - NovartisAlternative Names: NOV 1090; NOV 1401
Latest Information Update: 14 Feb 2017
At a glance
- Originator Novartis
- Class Monoclonal antibodies
- Mechanism of Action Factor XI inhibitors; Factor XIa inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Thrombosis